<DOC>
	<DOCNO>NCT00240266</DOCNO>
	<brief_summary>The purpose study investigate effect treatment rosuvastatin capacity plasma promote cholesterol efflux , first likely rate limit step reverse cholesterol transport .</brief_summary>
	<brief_title>Study High Density Lipoprotein Cholesterol ( HDL-C ) -Raising Mechanism Rosuvastatin ( CRESTOR™ ) Quantifying Key Steps Reverse Cholesterol Transport ( RCT )</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent male age 4565 insulin resistance central obesity LDLC &lt; 6 mmol/L plasma triglyceride &gt; =1.7 ≤5.5 mmol/L HDLC ≤1.2 mmol/L . total cholesterol &gt; 7mmol/L preexist cardiovascular disease , diabetes , proteinuria renal failure</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Dyslipaemia</keyword>
</DOC>